Your browser doesn't support javascript.
loading
Prognostic Significance of Prognostic Nutritional Index in Patients with Renal Cell Carcinoma: A Meta-Analysis.
Xiong, San-Chao; Hu, Xu; Lia, Thongher; Wang, Yao-Hui; Li, Xiang.
Afiliación
  • Xiong SC; West China School of Medicine/West China Hospital, Sichuan University, Chengdu, People's Republic of China.
  • Hu X; West China School of Medicine/West China Hospital, Sichuan University, Chengdu, People's Republic of China.
  • Lia T; West China School of Medicine/West China Hospital, Sichuan University, Chengdu, People's Republic of China.
  • Wang YH; West China School of Medicine/West China Hospital, Sichuan University, Chengdu, People's Republic of China.
  • Li X; Department of Urology, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
Nutr Cancer ; 74(3): 860-868, 2022.
Article en En | MEDLINE | ID: mdl-34060398
ABSTRACT
The prognostic nutrition index (PNI), based on the serum lymphocyte counts and albumin levels, has been introduced as a prognostic factor in various cancer. In the present study, we explore the prognostic significance of PNI in patients with renal cell carcinoma (RCC). A literature search of all publications was conducted using the Cochrane library, PubMed and Embase databases from inception to April 2020. A total of 12 studies consisting of 7,391 patients were enrolled in the present study. We found that low pretreatment PNI is significantly correlated to poor survival, including overall survival (OS) (P < 0.001), cancer-specific survival (CSS) (P = 0.002), progression-free survival/recurrence-free survival/disease-free survival (PFS/RFS/DFS) (P < 0.001). The age (P < 0.001), clear cell histology (P = 0.044), T3-T4 (P = 0.049), and Fuhrman grade 3-4 (P = 0.024) were significantly differed in the low and high pretreatment PNI group. In summary, low pretreatment PNI was associated with adverse clinicopathological features in patients with RCC. Besides, low pretreatment PNI was also an unfavorable factor of OS, CSS, and PFS/RFS/DFS in RCC patients, which could serve as an unfavorable factor. More studies with large participants are required to verify our results.Supplemental data for this article is available online at https//doi.org/10.1080/01635581.2021.1931702.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Nutr Cancer Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Nutr Cancer Año: 2022 Tipo del documento: Article